July 26, 2018. New products must provide a real and clinically meaningful benefit, not just a hope that the treatment works. Unfortunately, the clinical trial data presented today do not provide substantial evidence that mepolizumab [Nucala] provides this benefit for patients with COPD and high eosinophil counts.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
Letter to Members of Congress Opposing the “Accurate Labels Act”
July 11, 2018. We urge you to oppose this dangerous family-unfriendly legislation that: undermines the health of the American public; eliminates states’ existing ability to inform their citizens about the ingredients of products and the dangers that they may pose; and keeps Americans in the dark about the products they bring into their homes.
Read More »Letter from Nonprofits to DC Mayor and Other Officials About Dangers of Artificial Turf and Playgrounds
July 10, 2018. DC Nonprofits write to DC Officials about the dangers of artificial turf and playgrounds. Both environmental and health concerns are discussed, and officials are advised to stop the usage of this kind of turf around children.
Read More »NCHR Testimony at FDA on the Benefits and Risks of Systemic Fluoroquinolone Antibacterial Drugs
November 5, 2016. While quinolones can be life-saving drugs for certain types of infections, we must re-examine their safety and efficacy in light of new information to ensure the benefits outweigh the harms.
Read More »NCHR FDA Testimony on Remoxy as an Abuse-Deterrent Opioid
June 26, 2018: To reduce the opioid epidemic, the FDA must hold pharmaceutical companies to a high and truthful standard. Remoxy did not meet the FDA’s standards for oral abuse, and it remains unclear whether it can be abused intravenously. The safety of the excipient is also in question. Please carefully consider the risks of putting another drug with abuse-deterrent labeling on the market that could result in misuse and abuse in the real world. We urge this Advisory Committee to vote that the benefits of this drug do not outweigh its risks.
Read More »